enGene Therapeutics (ENGN) Current Assets (2022 - 2026)
enGene Therapeutics (ENGN) posted quarterly Current Assets of $270.0 million for Q2 2026, up 18.43% year-over-year from $228.0 million in Q2 2025, and down 6.64% quarter-over-quarter from $289.2 million in Q1 2026.
enGene Therapeutics (ENGN) Current Assets (2022 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported Current Assets for 5 consecutive years, with $270.0 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Current Assets rose 18.43% year-over-year to $270.0 million; the TTM figure through Apr 2026 stood at $270.0 million (up 18.43% YoY), while the FY2025 annual figure was $201.4 million, down 18.58% from the prior year.
- Current Assets fell to $270.0 million in Q2 2026 per ENGN's latest filing, from $289.2 million in the prior quarter.
- Across five years, Current Assets topped out at $289.2 million in Q1 2026 and bottomed at $22.6 million in Q4 2022.
- Historically, Current Assets has averaged $200.0 million across 5 years, with a median of $225.1 million in 2025.
- Annual changes were most pronounced in 2023 — Current Assets surged 278.34% — and 2025, when it decreased 19.56%.
- enGene Therapeutics' Current Assets stood at $22.6 million in 2022, then soared by 278.34% to $85.4 million in 2023, then jumped by 189.52% to $247.4 million in 2024, then dropped by 18.58% to $201.4 million in 2025, then soared by 34.07% to $270.0 million in 2026.
- Business Quant data shows ENGN's Current Assets at $270.0 million in Q2 2026, $289.2 million in Q1 2026, and $201.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.76 Bn |
| 10 | enGene Therapeutics | 124.11 Mn | 124.11 Mn | - | 270.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 270.00 Mn |
| Jan 31, 2026 | 289.22 Mn |
| Oct 31, 2025 | 201.39 Mn |
| Jul 31, 2025 | 211.31 Mn |
| Apr 30, 2025 | 227.97 Mn |
| Jan 31, 2025 | 222.32 Mn |
| Oct 31, 2024 | 247.36 Mn |
| Jul 31, 2024 | 262.69 Mn |
| Apr 30, 2024 | 269.61 Mn |
| Jan 31, 2024 | 89.58 Mn |
| Oct 31, 2023 | 85.44 Mn |
| Oct 31, 2022 | 22.58 Mn |